The Drug Enforcement Administration (DEA) placed the substance fospropofol, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into Schedule IV of the Controlled Substances Act. Fospropofol was approved by the FDA under the trade name Lusedra® for use as a drug product indicated for monitored anesthesia care sedation in adult patients undergoing diagnostic or therapeutic procedures. Fospropofol acts as a central nervous system depressant and elicits behavioral effects similar to Schedule IV sedative-hypnotics. The effective date of the final rule is November 5, 2009.
SOURCE: DEA Order, ¶40,388
For more information on this and related topics, consult the CCHFDA Food, Drug and Cosmetic Law Reporter.
Visit our News Library to read more news stories.
Food, Drug and Cosmetics Law Reporter
Everything you need to know about Food and Drug Regulations.Full-text source covering federal and state laws and regulations and court decisions that govern the safety, effectiveness, purity, packaging and labeling of food, drugs and cosmetics. Learn More » |
Medical Devices ReporterAccess the full text plus expert analysis of all laws and regulations governing the classification, approval, manufacture, and marketing of all medical diagnostic, and radiological devices. Learn More »
|
